Chronic treatment with novel nanoformulated micelles of rapamycin, Rapatar, protects diabetic heart against ischaemia/reperfusion injury

BACKGROUND AND PURPOSE: Enhanced mammalian target of rapamycin (mTOR) signalling contributes to the pathogenesis of diabetes and plays a critical role in myocardial ischaemia/reperfusion (I/R) injury. Rapatar is a novel nanoformulated micellar of rapamycin, a putative inhibitor of mTOR that has been...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Br J Pharmacol
Autors principals: Samidurai, Arun, Salloum, Fadi N, Durrant, David, Chernova, Olga B, Kukreja, Rakesh C, Das, Anindita
Format: Artigo
Idioma:Inglês
Publicat: John Wiley and Sons Inc. 2017
Matèries:
Research Papers
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5727242/
https://ncbi.nlm.nih.gov/pubmed/28967097
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bph.14059
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars